TrialOncoimmunology2021

An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.

Merve Hasanov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.